InVivoMAb Anti-Human CNR1/CB1 Nanobody (5D12) (HB822010)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet

Overview

Catalog No.

HB822010

Description

InVivoMAb Anti-Human CNR1/CB1 Nanobody (5D12) [5D12] (HB822010) is a alpaca monoclonal antibody detecting CNR1 in ELISA, Neutralization. Suitable for Human.

Species reactivity

Human

Applications

ELISA, Neutralization, WB

Host species

Alpaca

Isotype

VHH-8His-Cys-tag

Clone ID

5D12

Clonality

Monoclonal

Tested applications

Target

CNR1, CB1, CANN6, CB-R, CNR, Cannabinoid receptor 1

Endotoxin level

<0.01 EU/ug

Purity

>95% as determined by SDS-PAGE.

Purification

Purified by Nickel column.

Accession

P21554

RRID

InVivoMAb Anti-Human CNR1/CB1 Nanobody (5D12) (abinScience Cat# HB822010, RRID:AB_3727800)

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
WB	1:500-1:2000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Background

Cannabinoid receptor 1 (CNR1/CB1) is a ~52 kDa protein. G-protein coupled receptor for endogenous cannabinoids (eCBs), including N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids, such as delta(9)-tetrahydrocannabinol (THC). Mediates many cannabinoid-induced effects, acting, among others, on food intake, memory loss, gastrointestinal motility, catalepsy, ambulatory activity, anxiety, chronic pain. Signaling typically involves reduction in cyclic AMP. In the hypothalamus, may have a dual effect on mitochondrial respiration depending upon the agonist dose and possibly upon the cell type. Increases respiration at low doses, while decreases respiration at high doses.

1. Ryberg, E. et al. (2005) FEBS letters 579, 259-64. PMID: 15620723

2. Hua, T. et al. (2016) Cell 167, 750-762.e14. PMID: 27768894

3. Shao, Z. et al. (2016) Nature 540, 602-606. PMID: 27851727

4. Yang, X. et al. (2022) Nature chemical biology 18, 831-840. PMID: 35637350

5. Gérard, CM. et al. (1991) The Biochemical journal 279 ( Pt 1), 129-34. PMID: 1718258

6. Oddi, S. et al. (2012) British journal of pharmacology 165, 2635-51. PMID: 21895628

7. Niehaus, JL. et al. (2007) Molecular pharmacology 72, 1557-66. PMID: 17895407

8. Jourdan, T. et al. (2013) Nature medicine 19, 1132-40. PMID: 23955712

Note

For research use only. Not suitable for clinical or therapeutic use.

Images

SDS-PAGE

SDS-PAGE for InVivoMAb Anti-Human CNR1/CB1 Nanobody (5D12)
Bioactivity

Detects recombinant CNR1 (Catalog No: HB822012) in indirect ELISA.
Western blot

Western blot analysis was performed using anti-CNR1 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human CNR1 (Catalog No: HB822012)